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In this study, a completely water soluble tri-cationic porphyrin–EDTA conjugate was synthesized. We
present data demonstrating the tumoristatic effects of the novel fully water soluble cationic porphyrin
TMPy3PhenEDTA-P-Cl4 in the dark, in the medullary thyroid carcinoma cell lines MTC-SK and SHER-I
and weaker effects in the small intestinal neuroendocrine tumor cell line KRJ-I. In addition, cytotoxic
effects were also studied in normal human ﬁbroblasts that represent normal tissue and the results are
compared to the tumor cell lines.
 2011 Elsevier Inc. Open access under CC BY-NC-ND license.1. Introduction
Cationic porphyrins represent an expanding class of com-
pounds, which have several applications in biology, medicine and
catalysis and have been studied from the viewpoint of their role
as DNA cleavers [1–5]. Recent studies about the interaction of cat-
ionic porphyrins and their derivatives with DNA have moved por-
phyrin compounds into the spotlight of an alternative anticancer
strategy [3,6,7].
Small intestinal neuroendocrine tumors (SI-NETs) represent a
group of rare neoplasms that are derived from enterochromafﬁn
cells (ECs) [8–10]. Response rates to standard chemotherapy and
radiotherapy are low and surgery remains the only curative treat-
ment [11]. However, 60–80% of patients show metastases at the
time of diagnosis and curative surgery is only performed in <15%
of the cases [12].
Medullary thyroid carcinoma (MTC) is a neuroendocrine tumor
arising from the parafollicular C-Cells of the thyroid gland and 25%
of patients show distant metastases at the time of diagnosis
[13–15].sity Graz, Institute of Patho-
0 Graz, Austria (R. Pfragner).
.at (R. Pfragner), wolfgang.
C-ND license.Since both tumor types are known for their poor response to
standard chemotherapy and radiotherapy, there is a substantial
need for establishing new therapeutic strategies.
In thisworkwe present the synthesis of a fullywater soluble cat-
ionic porphyrin TMPy3PhenEDTA-P-Cl4 (Por-EDTA) 4 (Scheme 1),
functionalized with an ethylene-diamintetraacetic acid EDTA
moiety, a typical chelator for Fe or Cu ions [16].
The presence of Fe in ribonucleotide reductase is vital for prolif-
eration owing to its role in catalyzing the rate-limiting step of DNA
synthesis (i.e. the conversion of ribonucleotides into deoxyribonu-
cleotides). The importance of Fe is highlighted by the fact that Fe
deprivation leads to G1-S arrest and apoptosis [17]. Neoplastic cells,
in particular, have a high Fe requirement due to their rapid prolifer-
ation. To attainmore Fe, neoplastic cells express higher levels of the
transferrin receptor 1 (TfR1) and take up Fe more rapidly than their
normal counterparts. This is reﬂected by the ability of tumors to be
radiolocalized using 67Ga, which binds to the Fe transport protein,
transferrin, for delivery via TfR1 [18]. Similarly, phosphoro-thiolat-
ed antisense TfR1 oligonucleotides targeted to TfR1 mRNA showed
selective anticancer activity [19], conﬁrming the importance of Fe
in cancer cell growth. These observations show how Fe chelation
maybe a suitable therapeutic strategy for cancer treatment. In addi-
tion to Fe, Cu is also a promising therapeutic target due to its key
role in angiogenesis [20]. Chelation of Cu suppresses several angio-
genic mediators, including vascular endothelial growth factor-1,
ﬁbroblast growth factor-1, interleukin (IL)-1, IL-6, IL-8, and nuclear
factor-jB [21]. Because angiogenesis is critical for tumormetastasis
Scheme 1. Chemical structure of TMPy3PhenEDTA-P-Cl4 4.
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novel therapeutic strategy for cancer chemotherapy.
We herein show the antiproliferative effects of a completely
water soluble cationic porphyrin–EDTA hybrid derivative 4 in the
small intestinal neuroendocrine tumor (SI-NET) cell line KRJ-I
[22], the medullary thyroid carcinoma (MTC) cell line MTC-SK
[23], SHER-I [24] and the human ﬁbroblast cell line HF-SAR [25].2
Scheme 2. Reaction scheme to obtain TMPy3PhenEDTA-P-Cl4 4 and reaction condi
2-nitrobenzaldehyde, 4.5 mmol 4-pyridine-carboxaldehyde reﬂuxed (120 min), (ii) redu
Extensive Column Chromatography and HPLC were applied to purify the reaction produ2. Experiments
2.1. Materials and methods
All chemical reactions were carried out under nitrogen in de-
gassed solvents, which were dried using conventional methods.
Preparative thin layer chromatography was carried out on silica
gel 60 F254 (Merck) 0.2 mm plates. The porphyrin precursors were
visualized by UV–visible absorption (245–365 nm). Flash column
chromatography was carried out using silica gel 60 (Merck)
230–400 mesh and distilled solvents. Pyrrole was freshly distilled
before use. Other chemicals were purchased as reagent grade and
applied without further puriﬁcation.2.2. Instruments
NMR spectra were recorded on a Bruker DRX NMR spectrometer
equipped with a cryogenically cooled probe operating at 500 MHz
for 1H and 125.725 MHz for 13C. 1H chemical shifts and 13C
chemical shifts are reported relative to tetramethylsilane (TMS)
and were reported as d (ppm). Mass spectra were collected on a
Finnigan LCQ DecaXPplus Ion trap Mass spectrometer with ESI
ion source and an Agilent ESI-Q-TOF 6250. Porphyrin samples were
dissolved in chloroform/methanol (1:1) or methanol and were2
2
tions to obtain compound 4: (i) Propionic acid/propionic anhydride, 1.5 mmol
ction with SnCl2 in HCl, (iii) amidation with EDTA-di-anhydride in DMSO and TEA.
cts.
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Fig. 1. Cytotoxic effects of different concentrations (1, 10 and 20 lM) of
TMPy3PhenEDTA-P-Cl4 4 in MTC cell lines: effects of TMPy3PhenEDTA-P-Cl4 4 on
cell viability quantiﬁed using WST-1 assay. Comparison of antiproliferative activity
of TMPy3PhenEDTA-P-Cl4 4: a decrease in counted cells was noted in MTC-SK cells
compared to untreated control.
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0.30 ml/h. The source and desolvation temperatures were 80 and
120 C, respectively with a capillary voltage of 3.1 kV, sampling
cone voltage of 58 V, and the extractor cone to 3 V. The collision
energy was set to 14 eV and Argon was used as collision gas for
the CID experiments, which was adjusted to a pressure of
1.7  104 mbar. UV-absorption spectra of porphyrins were carried
out on a Varian CARY 100 Bio UV/visible-spectrometer equipped
with Cary Temperature Controller (5 mM NaCacodylate, 20 mM
NaCl, pH 7.0 buffer).
2.3. Synthesis of porphyrin precursors 1, 2 and 3
The starting 5-(2-nitrophenyl)-10,15,20-tris(4-pyridyl)-porphy-
rin [TMPyPhenNO2P]Cl3 1 was obtained via two-step synthesis
with the mixed aldehyde reaction of pyrrole, pyridine-4-carbalde-
hyd [26]. This reaction gave the desired mononitroporphyrin in an
acceptable yield (12%). The subsequent reduction of the nitro
group into the amino group was carried out in a mixture of hydro-
chloric acid in the presence of an excess (12 equivalents) of
SnCl22H2O, while protecting the reaction mixture from the light.
The ﬁnal 5-(4-aminophenyl)-10,15,20-tris(4-pyridyl)-porphyrin
[TMPyPhenNH2P]Cl3 2 was obtained in 80% yield. The synthetic
scheme to obtain the Por-EDTA hybrids is shown in Scheme 2.
2.4. Synthesis of Por-EDTA hybrid 4 (5,10,15-tris(N-methylpyridi-
nium-4-yl)-20-(1-phenyl-2-(ethylene diamine-tetra acetic acid))-
21H,23H-porphyrin)
A mixture of 0.474 mmol TPy3(PhenNH2)1P 2 and 0.569 mmol
ethylenediaminetetraacetic acid dianhydride in dimethylsulfoxide
and triethylamine was stirred for 30 min under inert gas. Subse-
quently, water was added and compound 3 was extracted with
dichloromethane (DCM) and little amount of sodium chloride
was added to enhance the solubility in DCM. Puriﬁcation was per-
formed with column chromatography (CHCl3/hexane 1:1) and
product 3 was isolated in 90% yield. Step two was immediately
performed after work up, where to a mixture of 10 ml CH3NO2
and 10 ml CHCl3 (1:1 v/v) 0.2 mmol TPy3PhenEDTA1P 3 and
1.1 mmol methyliodide were added. This reaction mixture was
reﬂuxed for 90 h under argon atmosphere. The progress of the
N-methylation reaction can be monitored using silica gel TLC and
an eluent containing ACN:H2O (sat. KNO3):H2O 8:1:1 (v/v). Then
the reaction mixture was evaporated to dryness, dissolved in
deionized water and the impurities were extracted with CHCl3.
Compound 4 was then ﬂushed through an amberlite (A-21) Cl
ion exchange resin and puriﬁed with reversed phase HPLC (eluent
mixture: ACN/MeOH = 50/1).
The remaining ACN/MeOH fraction was then evaporated to dry-
ness which gave the chloride salt of TMPy3PhenEDTA1P-Cl3 4 in
90% yields.
1H NMR (500 MHz, D2O, 303.57 K, d [ppm]): 8.93 (d, J = 5.83 Hz,
6H, pyridyl-3,5-H), 8.85 (d, J = 4.1 Hz, 2H, b-pyrrole-H), 8.55 (d,
J = 4.1 Hz, 2H, b-pyrrole-H), 8.29 (d, J = 5.83, 6H, pyridyl-2,6-H),
8.19 (d, J = 4.1 Hz, 2H, b-pyrrole-H), 7.76 (d, J = 4.1 Hz, 2H, b-pyr-
role-H) 6.95–6.85 (m, 4H, phenyl-H), 4.39 (s, 9H, N+–CH3), 2.59
(br, m, 12H, –CH2–).
13C NMR (125 MHz, D2O, 303.57 K, d [ppm]): 177.1 (q, –COOH),
168.4 (q, –NHCO–), 153.0 (q, pyridyl-1-C), 149.0 (pyridyl-CH),
147.7 (b-pyrrole-CH), 146.6 (b-pyrrole-CH), 129.7 (b-pyrrole-CH),
129.1 (pyridyl-CH), 128.7 (b-pyrrole-CH), 137.2 (q, phenyl-C),
124.4 (phenyl-CHs), 51.3 (–N+–CH3), 36,4 (–CH2–) (q – quaternary
carbon).
ESI-MS (4 in CHCl3: MeOH (1:1), positive ion mode):
m/z = 317.23 ([M]3+), 475.71 ([M]2+), theoretical mass = 951.39
(Sum formular = C54H51N10O7).UV–Vis (4 in aqueous buffer solution containing 5 mM NaCaco-
dylate, 20 mM NaCl, pH 7.0): kmax (nm) (loge) = 421.3 nm (4.92),
512.6 (3.31), 547.4 (3.16), 589.4 (3.05).
2.5. Cell culture conditions
MTC-SK, SHER-I and KRJ-I cells were cultured in Ham’s
F12/M199 (1:1) (Biowhittaker, Verviers, Belgium) supplemented
with 10% FBS (PAA Laboratories, Pasching, Austria). HF-SAR cells
were maintained in Eagle’s minimal essential medium (Biowhit-
taker, Verviers, Belgium) containing 10% FBS All cell lines were
Mycoplasma free and maintained without antibiotics at 37 C and
5% CO2.
2.6. Cell counting
MTC-SK, SHER-I and KRJ-I cells were incubated in 24 well plates
(2  105 cells/ml) and treated with different concentrations of Por-
EDTA for 24, 48 and 72 h, Aqua bidest was used as negative control.
Cell counts were performed using CASY-1 Cell Counter & Analyzer
TTC (Schärfe System, Reutlingen, Germany). Each sample was
quantiﬁed three times.
2.7. WST-1 cell proliferation assay
MTC-SK, SHER-I, KRJ-I and HF-SAR cells were seeded in 24 well
plates (2  105 cells/ml) and treated with different concentrations
of porphyrin 4 for 24, 48 and 72 h. After incubation the cells were
G. Schwach et al. / Bioorganic Chemistry 40 (2012) 108–113 111carefully pipetted to obtain single cells. One-hundred microliters
cell suspension was transferred into a 96 well plate. After adding
10 ll of WST-1 reagent an additional incubation of 2 h at 37 C
and 5% CO2 was performed. Then the samples were analyzed spec-
trophotometrically by measuring the absorbance at 450 nm using
an ELISA plate reader (Molecular Devices Thermomax Plate Reader,
Pegasus Scientiﬁc Inc., Rockville, USA). The adherent cell line HF-
SAR was seeded directly into the 96 well plates at a density of
1  105 cells/ml. After adherence to the plates the cells were trea-
ted with porphyrin 4 and viability was measured at 24, 48 and 72 h
as described above. Values of each sample (n = 6) were averaged
and normalized to control.
2.8. Hoechst 33258 staining
Hoechst stain solution (Bisbenzimide H33258) H6024 (Sigma–
Aldrich); MTC-SK cells were seeded in 6 well plates (Sarsted, Wr
Neudorf, Austria) (2  105 cells/ml) and treated with 10 lM Por-
EDTA for 48 h. Thereafter the cell suspensions were centrifuged
at 300 g, the supernatant removed and cell pellet washed with
Hoechst 33258:PBS (1:50) and incubated 15 min at 37 C. After a
new centrifugation at 300 g cells were resuspended in PBS and
examined using a LEICA DM 4000B microscope with ultraviolet
excitation at 300–500 nm (Leica EL 6000 BZ01).0
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Fig. 2. Cytotoxic effects of different concentrations (1, 10 and 20 lM) of
TMPy3PhenEDTA-P-Cl4 4 in KRJ-I cell line: effects of TMPy3PhenEDTA-P-Cl4 4 on
cell viability quantiﬁed using WST-1 assay. Only a small concentration dependent
decrease in counted cells was noted in KRJ-I cells compared to control. (For
interpretation of the references to colour in this ﬁgure legend, the reader is referred
to the web version of this article.)2.9. Assessment of caspase-3/7 activity
MTC-SK cells were plated in 96-well plates and treated with
porphyrin 4 (5 lM and 10 lM) up to 72 h or left untreated. Cas-
pase-Glo 3/7 Reagent and Rhodamine-110 Substrate were added
to wells, and luminescence and ﬂuorescence were recorded start-
ing at one hour. Luminescence was recorded on a Dynex MLX
luminometer and ﬂuorescence was recorded on a LabSystems Flu-
oroscan Ascent ﬂuorimeter (485Ex/527Em). Results were plotted
as signal-to-noise ratios. Background readings were determined
from wells containing culture medium without cells.
3. Results and discussion
3.1. Cell survival assays
It is an essential prerequisite to understand the mechanism of
inhibition of tumor cells to develop anticancer drugs based on cat-
ionic porphyrinoid systems. Recently, the tumor inhibitionmode of
cationic porphyrin was described as down regulation of c-MYC and
human telomerase reverse transcriptase expression [6].
To verify and quantify the inhibition of tumor cell growth after
incubation with porphyrin 4, we ﬁrst applied WST-1 cell prolifera-
tion assays in vitro in medullary thyroid carcinoma cells and small
intestinal neuroendocrine tumor cells [3]. Cytotoxic data were ex-
pressed as IC50 values (the concentration of the test agent inducing
50% reduction in cell numbers compared with control cultures),0
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Fig. 3. Cytotoxic effects of different concentrations (1, 10 and 20 lM) of
TMPy3PhenEDTA-P-Cl4 4 in human SHER-I cell line: effects of TMPy3PhenEDTA-P-
Cl4 4 on cell viability quantiﬁed using WST-1 assay and Casy-1 Cell Counter
analyses. (For interpretation of the references to colour in this ﬁgure legend, the
reader is referred to the web version of this article.)
112 G. Schwach et al. / Bioorganic Chemistry 40 (2012) 108–113and the corresponding IC50 values are 5.1 lM for MTC-SK, 9.3 lM
for SHER-I and 37.2 lM for KRJ-I.
Additionally, cell counting conﬁrmed results found by the WST-
1 studies. In MTC-SK cells and SHER-I cells porphyrin 4 had a high0
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Fig. 4. Cytotoxic effects of different concentrations (1, 10 and 20 lM) of
TMPy3PhenEDTA-P-Cl4 4 in human ﬁbroblast cell line HF-SAR: effects of
TMPy3PhenEDTA-P-Cl4 4 on cell viability quantiﬁed using WST-1 assay and
Casy-1 Cell Counter analyses. (For interpretation of the references to colour in
this ﬁgure legend, the reader is referred to the web version of this article.)
Fig. 5. Incubation of MTC-SK cells with TMPy3PhenEDTA-P-Cl4 4. Nuclear staining
was performed using Hoechst 33258 (DAPI) dye. While no morphological changes
were evident in the control. Nuclear body fragments and irregular edges around the
nucleus were observed (white arrows), 10 lM TMPy3PhenEDTA-P-Cl4 4.
Fig. 6. Normalized effector caspase 3/7 activity after 48 and 72 h in MTC-SK cells.antiproliferative effect (Figs. 1 and 2), while cell proliferation data
of KRJ-I cells showed low values of growth inhibition (Fig. 3).
To further investigate effects of the novel porphyrin compound
4, WST-1 tests on normal tissue were performed. The cell viability
of HF-SAR cells treated with 4was even higher compared to the un-
treated control (see Fig. 4). Comparing the effects of porphyrin 4 in
the tumor cell lines and ﬁbroblast cell line, a constant decrease of
cell viability was noted in tumor cells, while, after an initial de-
crease in cell viability, ﬁbroblasts were not signiﬁcantly altered.
Using light microscopy an increase in cell debris and dead cells
was observed in tumor cell lines, while no signiﬁcant effect was
noted in ﬁbroblasts compared to the untreated control. These ﬁnd-
ings suggest a different mechanism in normal cells compared to tu-
mor cells.
3.2. Apoptosis of MTC-cells
We selected ﬁrst theMTC cells as our model system to carry out
investigations to elucidate the underlying intracellular signalling
pathway leading to the terminal cell death.
At ﬁrst, to identify if necrosis or apoptosis occurs in the tumor
cells, the morphology of cells was investigated by staining with
Hoechst 33258, a blue ﬂuorescent DNA dye. After performing this
standard staining protocol on the non-treated and treated MTC-
cells, the morphological changes such as chromatin condensation,
nuclear pyknosis and increased number of nuclear body frag-
ments became evident (Fig. 5B, marked with arrows). This mor-
phology features point to apoptosis as the predominant cell
death process.
To conﬁrm this assumption we performed the caspase-Glo 3/7
assay which is a luminescent assay that measures caspase-3 and -7
activities. Indeed, we investigated high caspase 3/7 activity after 48
and 72 hours after incubation with porphyrin 4 (Fig. 6).4. Conclusion
To conclude, our ﬁndings demonstrate a signiﬁcant antiprolifer-
ative effect of the novel water soluble tri-cationic porphyrin/EDTA
hybrid 4 in MTC cell line MTC-SK, while normal tissue was not sig-
niﬁcantly impaired.
G. Schwach et al. / Bioorganic Chemistry 40 (2012) 108–113 113The porphyrin 4 demonstrates a dose-dependent decrease in
mitochondrial activity in MTC (MTC-SK and SHER-I cell lines)
with IC50s of 5.1 lM and 9.3 lM, respectively. The tumoristatic
effects were accompanied by reduced cell proliferation quanti-
ﬁed by a Casy-1 Cell Counter and Analyser. Based on these
ﬁndings we conclude that EDTA modiﬁed porphyrins demon-
strate high cytotoxicity towards the investigated tumor cell lines.
Of particular interest is that no mitochondrial activity alterations
were noted in the ﬁbroblast derived cell line HF-SAR suggesting
antiproliferative speciﬁcity for tumor cells. Previous studies
described a speciﬁc accumulation of photo-sensitizers in tumor
tissue with less compound enhancement in normal tissue. We
hypothesize that a similar effect could be responsible for the
continuous decrease in tumor cell viability, while ﬁbroblasts
were only impaired initially and showed no constant inhibition
of cell proliferation.
Moreover, all experimental data supported the fact that such
porphyrin had good abilities to induce apoptosis preferably on
medullary thyroid carcinoma cell lines (MTC-SK) even in the dark
and thus, might be a new therapeutic option in treatment of
chemo-resistant neuroendocrine tumors. Different effects were
observed in KRJ-I cells, where low tumoristatic effects were
found.
Ongoing work focuses on the evaluation of how light exposure
alters the tumoristatic effects in the Por-EDTA 4/neuroendocrine
tumor cell line system.
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